Esperion Therapeutics (NASDAQ:ESPR) Cut to Hold at StockNews.com

StockNews.com cut shares of Esperion Therapeutics (NASDAQ:ESPR – Free Report) from a buy rating to a hold rating in a research note released on Friday morning. Several other research firms have also weighed in on ESPR. Needham & Company LLC lowered their price objective on Esperion Therapeutics from $8.00 to $6.00 and set a buy […]

Leave a Reply

Your email address will not be published.

Previous post Clean Harbors (NYSE:CLH) Raised to Strong-Buy at StockNews.com
Next post Fluent (NASDAQ:FLNT) Research Coverage Started at StockNews.com